# Enclomiphene Citrate *Also known as: Enclomifene, Enclomifene citrate, Androxal, EnCyzix, Enclo* Lifters discuss enclomiphene when they want to restart their own testosterone after androgen use, compare an oral option with TRT, or keep fertility in view. Another draw is the hope of a more tolerable alternative to Clomid. Trials support increased testosterone in selected men; feeling better, recovering after a cycle and preserving fertility are separate outcomes to assess. Educational information only — not medical advice. Modelled values are not individual measurements or dosing recommendations. ## Dosage & duration Named oral enclomiphene-citrate trials · men with secondary hypogonadism ### Phase II dose-ranging example **Published example — product-specific** - **Dose:** 6.25, 12.5 or 25 mg study arms - **How often:** Once daily by mouth - **How long:** 6 weeks Participants had low testosterone with low or inappropriately normal LH. The trial was not a general post-cycle regimen. - [Wiehle et al.2013 — enclomiphene PK and hormone response](https://pmc.ncbi.nlm.nih.gov/articles/PMC4155868/) — Original full-text phase II trial, 6.25/12.5/25 mg oral citrate daily for 6 weeks. Figure 4 is drug measured after 6 weeks, not first-dose plasma calibration; serum Tmax 2–3 h. AUC 0–24 at 25 mg about 4.5×12.5 mg, 7.5×6.25 mg. Drug and testosterone/LH peaks did not coincide. Checked 2026-10-09. ### Phase III examples **Published example — product-specific** - **Dose:** 12.5 mg, or 12.5 mg titrated to 25 mg - **How often:** Once daily by mouth - **How long:** 16 weeks Compared with testosterone gel and placebo; follow-up included hormones and semen measurements. - [Kim et al.2016 — enclomiphene versus testosterone gel](https://pubmed.ncbi.nlm.nih.gov/26496621/) — Original two phase III studies:overweight men 18–60 with secondary hypogonadism; 16 weeks; increased testosterone/LH/FSH and maintained sperm concentration, while gel lowered spermatogenesis. Sperm concentration is not proof of pregnancy or live birth. Checked 2026-10-09. - [FDA —2022 enclomiphene assessment slides](https://www.fda.gov/media/159042/download) — Enclomiphene section p 25:~10 h half-life, Tmax 2–3 h, non-dose-proportional Cmax. p 27:16-week trials 12.5 mg daily or 12.5 mg titrated to 25 mg. p 34/38/46:safety/clinical-benefit gaps and unsuccessful NDA 207959. Current OpenFDA approval searches for both ingredient spellings and NDA 207959 found no matches 2026-10-09; not a compounding-law determination. No FDA/EMA-approved enclomiphene dosing label was identified. Trial duration is not an established cycle length for unsupervised use. Dose-context sources checked: 2026-10-09. ## At a glance - **Why lifters discuss it:** Restart their own testosterone Sources or review notes: [1](https://pmc.ncbi.nlm.nih.gov/articles/PMC4155868/). - **Why compare it with TRT?:** Stimulate rather than replace Sources or review notes: [1](https://pmc.ncbi.nlm.nih.gov/articles/PMC4155868/), [2](https://pubmed.ncbi.nlm.nih.gov/26496621/). - **What counts as success?:** How you feel and relevant tests Sources or review notes: [4](https://www.ema.europa.eu/en/medicines/human/EPAR/encyzix). **Catalog evidence label (not clinical review):** Human RCT evidence ## Recovery, TRT alternatives and fertility - **After a cycle:** The cited low-testosterone trials do not establish a post-cycle recovery regimen. - **Instead of TRT:** Trials in selected men raised the body’s hormone signaling rather than supplying testosterone. - **Planning a family:** Maintained sperm counts in separate trial arms do not prove benefit when added to ongoing TRT. A higher testosterone result alone does not establish improved libido, recovery or fertility. Visual sources checked: 2026-10-09. - [Wiehle et al.2013 — enclomiphene PK and hormone response](https://pmc.ncbi.nlm.nih.gov/articles/PMC4155868/) — Original full-text phase II trial, 6.25/12.5/25 mg oral citrate daily for 6 weeks. Figure 4 is drug measured after 6 weeks, not first-dose plasma calibration; serum Tmax 2–3 h. AUC 0–24 at 25 mg about 4.5×12.5 mg, 7.5×6.25 mg. Drug and testosterone/LH peaks did not coincide. Checked 2026-10-09. - [Kim et al.2016 — enclomiphene versus testosterone gel](https://pubmed.ncbi.nlm.nih.gov/26496621/) — Original two phase III studies:overweight men 18–60 with secondary hypogonadism; 16 weeks; increased testosterone/LH/FSH and maintained sperm concentration, while gel lowered spermatogenesis. Sperm concentration is not proof of pregnancy or live birth. Checked 2026-10-09. ## Overview ## Why it comes up in bodybuilding After a cycle, the concern is often losing the testosterone level, sex drive or training momentum someone had while using androgens. People compare enclomiphene with Clomid and weigh recovery against staying on testosterone. That explains the interest; the conflicting experiences do not establish which plan works best. ## An oral alternative to TRT—or a PCT drug? Those are different questions. Published studies enrolled men with secondary hypogonadism and measured hormone responses to daily enclomiphene. They do not automatically establish a recovery regimen after a particular steroid cycle. The dose guide identifies the actual trial groups and duration rather than relabeling those numbers as a bodybuilding cycle. ## Will higher testosterone make me feel better? That is what people want to know. Some people report changes in energy or motivation, while others describe much better blood results with little improvement in libido. These are personal accounts, not response rates. Clinical trials established hormone changes more clearly than symptom benefit, so how someone feels remains a separate question from the testosterone number. ## Why choose it over Clomid? Clomid contains both enclomiphene and zuclomiphene. The attraction of the single isomer is the hope of a more tolerable experience. A retrospective study of 66 men reported fewer documented side effects after switching, but follow-up was shorter on enclomiphene and there was no washout between treatments. This does not establish a better PCT option or a personal dose conversion. ## Does it protect fertility while staying on TRT? The fertility interest is understandable: in the cited phase III trials, enclomiphene maintained sperm concentration while testosterone gel reduced it. Those were separate treatment groups. They do not prove that adding enclomiphene to ongoing injected testosterone preserves fertility. A semen analysis answers a different question from a testosterone blood test. ## What remains uncertain? No approved US/EU enclomiphene product was identified in this review. FDA and EMA assessments raise clinical-benefit and safety questions, including clotting concerns. The relative plot is useful for the stated drug-timing scenario; it cannot show hormonal recovery, libido or sperm production. ## Relative timing model Relative oral timing estimate **Output:** Enclomiphene Citrate: relative timing (relative units). Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength. Shows simplified enclomiphene timing, not testosterone or fertility. ### Timing assumptions and scale About 10 h elimination half-life from the 14-day oral-citrate trial; 2.5 h peak is an assumed midpoint of the 2–3 h range described in the 6-week trial and FDA review. One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales. - **Timing half-life used:** 10 hours - **Absorption half-life assumed:** 0.5705954 hours - **Reference amount for the relative scale:** 1 mg - Absorption half-life 0.570595 h is inferred from the selected 10 h tail and 2.5 h peak, not a published fitted rate. - One 1 mg declared citrate input peaks at 1 relative unit. This normalization is not a citrate-to-base conversion. - Dose-proportional scaling and repeated-dose addition are mathematical conveniences: observed drug exposure was not proportional across doses. - The 6-week study drug curve cannot be reused as a single-dose absolute calibration; no Cmax is invented. - Metabolites, CYP2D6 variability and hormonal feedback are not modeled. The drug curve does not estimate total testosterone, estradiol or sperm count. ### Model sources - [Wiehle et al.2013 — enclomiphene PK and hormone response](https://pmc.ncbi.nlm.nih.gov/articles/PMC4155868/) — Original full-text phase II trial, 6.25/12.5/25 mg oral citrate daily for 6 weeks. Figure 4 is drug measured after 6 weeks, not first-dose plasma calibration; serum Tmax 2–3 h. AUC 0–24 at 25 mg about 4.5×12.5 mg, 7.5×6.25 mg. Drug and testosterone/LH peaks did not coincide. Checked 2026-10-09. - [Wiehle et al.2014 —14-day randomized trial](https://doi.org/10.1089/jomh.2014.0006) — Original indexed abstract:52 men randomized to oral enclomiphene citrate 12.5/25/50 mg, gel or placebo daily for 14 days; elimination half-life about 10 h. Full numeric PK tables unavailable in accessible publisher view; no Cmax inferred. Checked 2026-10-09. - [FDA —2022 enclomiphene assessment slides](https://www.fda.gov/media/159042/download) — Enclomiphene section p 25:~10 h half-life, Tmax 2–3 h, non-dose-proportional Cmax. p 27:16-week trials 12.5 mg daily or 12.5 mg titrated to 25 mg. p 34/38/46:safety/clinical-benefit gaps and unsuccessful NDA 207959. Current OpenFDA approval searches for both ingredient spellings and NDA 207959 found no matches 2026-10-09; not a compounding-law determination. **Revision:** enclomiphene-citrate-oral-relative-2026-10 · version 1 ## Harm reduction - **Interaction notes:** No approved dosing label was identified. FDA/EMA reviews identified unresolved clinical-benefit and safety questions, including clotting risk; hormone and fertility outcomes need direct assessment. ## Sources and review notes Summary source check: 2026-10-09; see source notes 1, 2. This does not certify medical review of the whole page. ### Notes on the quick facts - **Why lifters discuss it:** PCT discussions focus on recovery and retaining progress; the trials here are not a validated post-cycle protocol. Source check: 2026-10-09; not a medical review. - **Why compare it with TRT?:** Trials raised testosterone and maintained sperm concentration in selected men with secondary hypogonadism. Source check: 2026-10-09; not a medical review. - **What counts as success?:** Personal accounts show why a higher testosterone result is not the whole answer to libido, energy or fertility questions. Source check: 2026-10-09; not a medical review. ### References 1. [Wiehle et al.2013 — enclomiphene PK and hormone response](https://pmc.ncbi.nlm.nih.gov/articles/PMC4155868/) — Original full-text phase II trial, 6.25/12.5/25 mg oral citrate daily for 6 weeks. Figure 4 is drug measured after 6 weeks, not first-dose plasma calibration; serum Tmax 2–3 h. AUC 0–24 at 25 mg about 4.5×12.5 mg, 7.5×6.25 mg. Drug and testosterone/LH peaks did not coincide. Checked 2026-10-09. 2. [Kim et al.2016 — enclomiphene versus testosterone gel](https://pubmed.ncbi.nlm.nih.gov/26496621/) — Original two phase III studies:overweight men 18–60 with secondary hypogonadism; 16 weeks; increased testosterone/LH/FSH and maintained sperm concentration, while gel lowered spermatogenesis. Sperm concentration is not proof of pregnancy or live birth. Checked 2026-10-09. 3. [FDA —2022 enclomiphene assessment slides](https://www.fda.gov/media/159042/download) — Enclomiphene section p 25:~10 h half-life, Tmax 2–3 h, non-dose-proportional Cmax. p 27:16-week trials 12.5 mg daily or 12.5 mg titrated to 25 mg. p 34/38/46:safety/clinical-benefit gaps and unsuccessful NDA 207959. Current OpenFDA approval searches for both ingredient spellings and NDA 207959 found no matches 2026-10-09; not a compounding-law determination. 4. [EMA — EnCyzix refusal and assessment](https://www.ema.europa.eu/en/medicines/human/EPAR/encyzix) — Refusal 06April 2018: hormone increases did not establish symptomatic benefit; venous-thromboembolism concern. Product remains listed as refused in record checked 2026-10-09. 5. [Wiehle et al.2014 —14-day randomized trial](https://doi.org/10.1089/jomh.2014.0006) — Original indexed abstract:52 men randomized to oral enclomiphene citrate 12.5/25/50 mg, gel or placebo daily for 14 days; elimination half-life about 10 h. Full numeric PK tables unavailable in accessible publisher view; no Cmax inferred. Checked 2026-10-09. 6. [Saffati et al.2024 — clomiphene-to-enclomiphene cohort](https://tau.amegroups.org/article/view/129106/html) — Full original article read 2026-10-09: 66 retrospective switchers; fewer documented adverse effects after switching. Shorter enclomiphene follow-up, no washout and selection bias; prior testosterone/hCG therapy excluded. Not a PCT trial. --- **Canonical URL:** https://anabolicplotter.com/compounds/enclomiphene/ **Methodology:** https://anabolicplotter.com/methodology/ **Plot:** https://anabolicplotter.com/plot?compound=enclomiphene